Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.
Essential hypertension presents a component of insulin resistance syndrome. Insulin resistance exists whenever normal concentration of hormone produces less than normal biologic response. This prospective clinical study included 15 patients (7 male and 8 female), with normal glucose tolerance, aged 53.24 +/- 6.60 years, BMI 26.97 +/- 1.24 kg/m2, with mild-to-moderate essential hypertension before and after ramipril treatment lasting 12 weeks. For assessment of peripheral insulin sensitivity and glucose effectiveness we used a reduced samples Bergman's Minimal Model method. At week 12, we noted a 50% elevation of mean insulin sensitivity index, but without achieving normal reference values (Si = 1.22 +/- 0.66 vs 1.78 +/- 0.8 x 10(-4) min/microU/ml). Glucose effectiveness, plasma lipids and electrolytes were relatively unchanged. Haemoglobin and platelet count were significantly decreased. Being metabolically neutral, with antithrombotic activity, ramipril can be recommended for treatment of patients with hypertension and insulin resistance, especially for patients with accompanied diabetes mellitus.